JP2003510291A5 - - Google Patents

Download PDF

Info

Publication number
JP2003510291A5
JP2003510291A5 JP2001526201A JP2001526201A JP2003510291A5 JP 2003510291 A5 JP2003510291 A5 JP 2003510291A5 JP 2001526201 A JP2001526201 A JP 2001526201A JP 2001526201 A JP2001526201 A JP 2001526201A JP 2003510291 A5 JP2003510291 A5 JP 2003510291A5
Authority
JP
Japan
Prior art keywords
influenza virus
antigen
dose
vaccine
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001526201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003510291A (ja
Filing date
Publication date
Priority claimed from GBGB9923176.3A external-priority patent/GB9923176D0/en
Application filed filed Critical
Publication of JP2003510291A publication Critical patent/JP2003510291A/ja
Publication of JP2003510291A5 publication Critical patent/JP2003510291A5/ja
Pending legal-status Critical Current

Links

JP2001526201A 1999-09-30 2000-09-27 新規組成物 Pending JP2003510291A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9923176.3 1999-09-30
GBGB9923176.3A GB9923176D0 (en) 1999-09-30 1999-09-30 Novel composition
PCT/EP2000/009509 WO2001022992A2 (en) 1999-09-30 2000-09-27 Influenza vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007248790A Division JP2008001725A (ja) 1999-09-30 2007-09-26 新規組成物

Publications (2)

Publication Number Publication Date
JP2003510291A JP2003510291A (ja) 2003-03-18
JP2003510291A5 true JP2003510291A5 (enExample) 2007-11-15

Family

ID=10861908

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2001526201A Pending JP2003510291A (ja) 1999-09-30 2000-09-27 新規組成物
JP2007248790A Withdrawn JP2008001725A (ja) 1999-09-30 2007-09-26 新規組成物
JP2011225072A Ceased JP2012021030A (ja) 1999-09-30 2011-10-12 新規組成物
JP2014162298A Pending JP2014205726A (ja) 1999-09-30 2014-08-08 新規組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2007248790A Withdrawn JP2008001725A (ja) 1999-09-30 2007-09-26 新規組成物
JP2011225072A Ceased JP2012021030A (ja) 1999-09-30 2011-10-12 新規組成物
JP2014162298A Pending JP2014205726A (ja) 1999-09-30 2014-08-08 新規組成物

Country Status (15)

Country Link
US (2) US7238349B1 (enExample)
EP (4) EP3103473A1 (enExample)
JP (4) JP2003510291A (enExample)
AT (2) ATE309821T1 (enExample)
AU (1) AU774921B2 (enExample)
BR (1) BR0014386A (enExample)
CA (2) CA2616210C (enExample)
CY (2) CY1111908T1 (enExample)
DE (3) DE60024112T2 (enExample)
DK (2) DK1216053T3 (enExample)
ES (2) ES2250193T3 (enExample)
GB (1) GB9923176D0 (enExample)
HK (1) HK1048434B (enExample)
PT (1) PT1618889E (enExample)
WO (1) WO2001022992A2 (enExample)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678345A (zh) 2002-04-26 2005-10-05 米迪缪尼疫苗股份有限公司 制备流感病毒的多质粒系统
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
ATE426412T1 (de) * 2003-01-30 2009-04-15 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
AU2012201973B2 (en) * 2003-02-25 2014-05-22 Medimmune, Llc Methods of producing influenza vaccine compositions
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
CN101804202B (zh) 2003-02-25 2014-06-18 米迪缪尼有限公司 制备流感疫苗组合物的方法
TWI350174B (en) * 2003-03-12 2011-10-11 Wyeth Corp Adjuvanted bovine vaccines
EP1697521B1 (en) 2003-12-23 2010-06-02 MedImmune, LLC Multi plasmid system for the production of influenza virus
CA2559371C (en) 2004-03-09 2014-07-08 Chiron Corporation Influenza virus vaccines
PT1789084E (pt) 2004-09-09 2011-02-22 Novartis Vaccines & Diagnostic Redução de riscos iatrogénicos pontenciais associados às vacinas contra a gripe
CA2586690A1 (en) 2004-11-03 2006-06-15 Novartis Vaccines And Diagnostics, Inc. Influenza vaccination
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
KR20070116651A (ko) * 2005-03-23 2007-12-10 글락소스미스클라인 바이오로지칼즈 에스.에이. 조성물
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
HUE051122T2 (hu) 2005-11-04 2021-03-01 Seqirus Uk Ltd Sejttenyészetben növesztett influenzavírusból elõállított nemvirion anti-géneket tartalmazó adjuvált vakcinák
WO2007052061A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
CA2628379A1 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Adminstration routes for priming/boosting with influenza vaccines
EP1951298A1 (en) 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted influenza vaccines including cytokine-inducing agents
AU2006310341B2 (en) * 2005-11-04 2011-01-06 Novartis Vaccines And Diagnostics Limited Influenza vaccines extemporaneously adsorbed to aluminium adjuvants
US8697087B2 (en) 2005-11-04 2014-04-15 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
EP2377552A3 (en) 2005-11-04 2013-05-15 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines with reduced amount of emulsion adjuvant
US20090047353A1 (en) 2005-11-04 2009-02-19 Novartis Vaccines And Diagnostics Srl Changing th1/th2 balance in split influenza vaccines with adjuvants
EP3753574A1 (en) 2006-01-27 2020-12-23 Seqirus UK Limited Influenza vaccines containing hemagglutinin and matrix proteins
CA2646349A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
US9072701B2 (en) * 2006-04-21 2015-07-07 St. Jude Children's Research Hospital Avian influenza viruses, vaccines, compositions, formulations, and methods
EP2035035A2 (en) 2006-06-09 2009-03-18 Novartis AG Immunogenic compositions for streptococcus agalactiae
WO2007144772A2 (en) * 2006-06-15 2007-12-21 Novartis Ag Adjuvant-sparing multi-dose influenza vaccination regimen
US20080014217A1 (en) * 2006-07-17 2008-01-17 Emmanuel Jules Hanon Influenza vaccine
DK2422810T3 (da) * 2006-07-17 2014-11-24 Glaxosmithkline Biolog Sa Influenzavaccine
CA2583555C (en) * 2006-07-17 2020-01-07 Glaxosmithkline Biologicals S.A. Influenza vaccine
JP5639760B2 (ja) 2006-07-17 2014-12-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザワクチン
GB0614460D0 (en) * 2006-07-20 2006-08-30 Novartis Ag Vaccines
KR20090057015A (ko) 2006-09-11 2009-06-03 노파르티스 아게 난을 사용하지 않는 인플루엔자 바이러스 백신의 제조
HRP20130023T1 (hr) * 2006-10-12 2013-02-28 Glaxosmithkline Biologicals S.A. Cjepivo koje sadrži emulziju ulje u vodi kao adjuvans
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
EA200900784A1 (ru) 2006-12-06 2009-12-30 Новартис Аг Вакцины, включающие антиген из четырех штаммов вируса гриппа
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
CN101085348B (zh) * 2007-06-18 2010-08-18 南京农业大学 用于禽流感灭活抗原的鼻腔免疫复合佐剂
ES2523587T3 (es) 2007-06-18 2014-11-27 Medimmune, Llc Virus influenza B que tienen alteraciones en el polipéptido hemaglutinina
SI2185191T1 (sl) 2007-06-27 2012-12-31 Novartis Ag Cepiva proti influenci z majhnimi dodatki
WO2009006420A2 (en) * 2007-06-29 2009-01-08 Avianax, Llc Vaccine production for pathogenic bird viral diseases
US8084594B2 (en) * 2007-07-13 2011-12-27 The United States Of America As Represented By The Secretary Of Agriculture H2N3 influenza A viruses and methods of use
ES2588705T3 (es) 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
GB0810305D0 (en) * 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2227251A1 (en) 2007-12-06 2010-09-15 GlaxoSmithKline Biologicals SA Influenza composition
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2008339631B2 (en) 2007-12-24 2014-07-24 Novartis Ag Assays for adsorbed influenza vaccines
WO2009111486A2 (en) * 2008-03-04 2009-09-11 The Regents Of The University Of California Reversing the immune decline of aging by a nutraceutical antioxidant in mice
CA2716399C (en) 2008-03-05 2020-07-21 Pierre Chouvenc Process for stabilizing an adjuvant containing vaccine composition
AU2009227674C1 (en) * 2008-03-18 2015-01-29 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
US9144606B2 (en) * 2008-04-21 2015-09-29 Nanobio Corporation Nanoemulsion influenza vaccine
CN102056622B (zh) 2008-06-05 2016-04-06 免疫疫苗技术有限公司 包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物
WO2009156852A1 (en) 2008-06-25 2009-12-30 Novartis Ag Rapid responses to delayed booster immunisations
WO2010012045A1 (en) 2008-08-01 2010-02-04 Gamma Vaccines Pty Limited Influenza vaccines
RU2400536C1 (ru) * 2009-01-11 2010-09-27 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУП ГНЦ ВБ "Вектор" Роспотребнадзора) ШТАММ ВИРУСА ГРИППА ПТИЦ A/common gull/Chany/2006 H5N1 СУБТИПА ДЛЯ ПРИГОТОВЛЕНИЯ АНТИГЕНСОДЕРЖАЩЕГО ДИАГНОСТИЧЕСКОГО ИЛИ ВАКЦИННОГО ПРЕПАРАТА
AU2010212550B2 (en) 2009-02-10 2016-03-10 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
BRPI1009828A2 (pt) 2009-03-24 2019-03-12 Novartis Ag adjuvante de proteína de ligação de fator h meningocócica
EP2424565A1 (en) 2009-04-27 2012-03-07 Novartis AG Adjuvanted vaccines for protecting against influenza
CA2763440A1 (en) 2009-05-29 2010-12-02 Novartis Ag Assays for influenza virus hemagglutinins
BR112012008338A2 (pt) 2009-09-10 2019-09-24 Novartis Ag combinação de vacinas contra doenças do trato respiratório.
WO2011036220A1 (en) * 2009-09-25 2011-03-31 Glaxosmithkline Biologicals S.A. Immunodiffusion assay for influenza virus
MX2012004067A (es) 2009-10-09 2012-08-03 Cbio Ltd Variantes de la chaperonina 10.
PT2356983E (pt) 2009-12-03 2013-04-23 Novartis Ag Circulação dos componentes durante a homogeneização da emulsão
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DK2380558T4 (da) 2009-12-03 2020-01-27 Novartis Ag Arrangement af interaktions- og modtrykskamre til mikrofluidisering
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
CL2012001399A1 (es) 2009-12-03 2013-03-08 Novartis Ag Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion.
ES2558056T3 (es) 2009-12-03 2016-02-01 Novartis Ag Filtración hidrófila durante la fabricación de adyuvantes para vacunas
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
ES2453316T5 (es) 2010-05-12 2017-07-18 Novartis Ag Procedimientos mejorados para preparar escualeno
EP2614163B1 (en) 2010-09-07 2016-01-06 Novartis AG Generic assays for detection of mammalian reovirus
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
EP2667891B1 (en) 2011-01-27 2021-10-06 Gamma Vaccines Pty Limited Combination vaccines
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
WO2013088367A1 (en) 2011-12-12 2013-06-20 Novartis Ag Assay for influenza virus hemagglutinins
WO2013098589A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
KR102055176B1 (ko) 2012-03-23 2019-12-12 피트니 파마슈티컬스 피티와이 리미티드 암 치료용 키나제 저해제
AU2013271338B2 (en) 2012-06-05 2018-05-24 The Australian National University Vaccination with interleukin-4 antagonists
EP2880154B1 (en) 2012-08-03 2019-05-15 Sanofi Pasteur SA Production of infectious influenza viruses
EP3202397B1 (en) 2012-08-06 2019-09-25 Pitney Pharmaceuticals Pty Limited Compounds for the treatment of mtor pathway related diseases
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
KR102255753B1 (ko) 2012-12-17 2021-05-26 뉴사우스 이노베이션즈 피티와이 리미티드 뮤신 관련 질환의 치료
US10357538B2 (en) 2012-12-24 2019-07-23 Northern Sydney Local Health District Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
RU2523614C1 (ru) * 2013-04-09 2014-07-20 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Вакцина против гриппа и способ ее получения
WO2015000014A1 (en) 2013-07-01 2015-01-08 Newsouth Innovations Pty Limited Diagnosis and treatment of autoimmune diseases
WO2015006384A1 (en) * 2013-07-09 2015-01-15 Texas Tech University System Universal influenza vaccine
KR20160036669A (ko) * 2013-07-31 2016-04-04 주식회사 쿠라레 투명성, 열 균열 현상 억제가 우수한 폴리비닐 아세탈 필름
EP3226904B1 (en) 2014-12-02 2019-03-06 Novartis AG Manufacture of surfactant-containing compositions
MY191539A (en) 2015-03-26 2022-06-30 Gpn Vaccines Pty Ltd Streptococcal vaccine
EP3313439A2 (en) 2015-06-26 2018-05-02 Seqirus UK Limited Antigenically matched influenza vaccines
AU2016290603B2 (en) 2015-07-07 2022-06-02 Seqirus UK Limited Influenza potency assays
CN105251002B (zh) * 2015-11-13 2019-02-15 中国人民解放军第三军医大学 一种水包油型纳米乳佐剂及其mrsa纳米乳佐剂疫苗和制备方法
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
CA3057171A1 (en) 2017-03-30 2018-10-04 The University Of Queensland Chimeric polypeptides containing virus fusion ectodomain and complementary heptad repeats and uses thereof
AU2018328291B2 (en) 2017-09-08 2022-10-27 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
AU2021252164A1 (en) 2020-04-09 2022-12-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
CN116171166A (zh) 2020-06-30 2023-05-26 塞其里斯英国有限公司 水包油乳液佐剂的冷过滤
CN111803625B (zh) * 2020-09-09 2020-12-18 天津中逸安健生物科技有限公司 一种亚单位流感疫苗裂解剂及其应用
WO2025019631A1 (en) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD155875A1 (de) 1980-12-31 1982-07-14 Willy Nordheim Verfahren zur herstellung eines ballaststoffarmen inaktivierten influenzaimpfstoffes
DD211444A3 (de) 1982-08-19 1984-07-11 Saechsisches Serumwerk Verfahren zur herstellung von influenza-impfstoffen
GB8300467D0 (en) 1983-01-08 1983-02-09 Wellcome Found Equine influenza
DD300833A7 (de) 1985-10-28 1992-08-13 Saechsische Landesgewerbefoerd Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8821049D0 (en) * 1988-09-08 1988-10-05 Health Lab Service Board Method & composition for treatment & prevention of viral infections
US5149531A (en) * 1990-06-27 1992-09-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
US5589174A (en) * 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
AU6141094A (en) * 1993-02-19 1994-09-14 Smithkline Beecham Biologicals (Sa) Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
JPH08506592A (ja) * 1993-02-19 1996-07-16 スミスクライン・ビーチャム・コーポレイション ３−ｏ−脱アシル化モノホスホリル脂質Ａ含有のインフルエンザワクチン組成物
WO1994021292A1 (en) 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
US6387378B1 (en) * 1993-09-09 2002-05-14 George P. Shibley Device for storage and mucosal delivery of biological or pharmaceutical materials to animals
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE280585T1 (de) * 1994-02-24 2004-11-15 Micro Pak Inc Impfstoffe, die paucilamelläre lipidvesikel als adjuvans enthalten
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5916879A (en) * 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
WO1998030228A1 (en) * 1997-01-13 1998-07-16 Emory University Compounds and their combinations for the treatment of influenza infection
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
AU1145699A (en) * 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
HUP0101139A3 (en) * 1997-12-02 2003-11-28 Powderject Vaccines Inc Madiso Transdermal delivery of particulate vaccine compositions
EP1064302A1 (en) * 1998-03-20 2001-01-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
AT407958B (de) * 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
HUP0202846A3 (en) * 1999-09-24 2003-12-29 Smithkline Beecham Biolog Intranasal influenza virus vaccine
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
KR20070116651A (ko) * 2005-03-23 2007-12-10 글락소스미스클라인 바이오로지칼즈 에스.에이. 조성물
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
EP2377552A3 (en) 2005-11-04 2013-05-15 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines with reduced amount of emulsion adjuvant
JP5639760B2 (ja) * 2006-07-17 2014-12-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザワクチン
US20080014217A1 (en) * 2006-07-17 2008-01-17 Emmanuel Jules Hanon Influenza vaccine
DK2422810T3 (da) * 2006-07-17 2014-11-24 Glaxosmithkline Biolog Sa Influenzavaccine
PE20090146A1 (es) * 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
EP2227251A1 (en) * 2007-12-06 2010-09-15 GlaxoSmithKline Biologicals SA Influenza composition

Similar Documents

Publication Publication Date Title
JP2003510291A5 (enExample)
EP1526172B1 (en) Process for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process
KR100927517B1 (ko) 생균 백신
KR101188382B1 (ko) 수중유 에멀젼 인플루엔자 백신
Lee et al. New vaccines against influenza virus
AU774921B2 (en) Novel composition
Skhodova et al. The impact of adjuvanted and non-adjuvanted influenza vaccines on the innate and adaptive immunity effectors
KR20020038771A (ko) 비내 인플루엔자 바이러스 백신
EP2488205B1 (en) Recombinant human cc10 protein for treatment of influenza
Hua et al. Protective efficacy of intranasal inactivated pseudorabies vaccine is improved by combination adjuvant in mice
US5698433A (en) Method for producing influenza virus and vaccine
Hnuma et al. Characteristics of Cytotoxic T Lymphocytes Directed to Influenza Virus Haemagglutinin Elicited by Immunization with Muramyldipeptide‐Influenza Liposome Vaccine
WO2021040439A1 (ko) 신규한 핵산을 기반으로 하는 인플루엔자 백신 조성물
Uchida Development of a cytotoxic T‐lymphocyte‐based, broadly protective influenza vaccine
CN120888511B (zh) 一种qmc流感毒种及其制备方法和应用
CN101274097B (zh) 喷雾流行性感冒疫苗组合物及其制备方法
Shivanandappa et al. WE WILL OVERCOME COVID 19 TOO…
JAFFE et al. Kinetics and specificity at the clonal level of the cytotoxic T lymphocyte response to influenza pneumonia
CN115869391A (zh) 可吸入型疫苗在预防感染新型冠状病毒所引发的疾病中的用途
CN114561364A (zh) 高效扩增人流感病毒的方法和试剂
Choppin et al. Oligopeptides as specific antiviral agents
US20020004050A1 (en) Vaccines
WO1997007818A1 (en) Vaccines
HK1142093B (en) Process for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process
HK1019233B (en) Animal cells and processes for the replication of influenza viruses